Page 9 - Flipbook
P. 9
Prostate cancer heterogeneity
• Prostate cancer is a highly heterogeneous group of diseases
• Intra-patient heterogeneity
• Admixed in gross biopsy
• RB1 loss; AR-V7; WNT aberrations
• Inter-patient heterogeneity
• BRCA2/ATM/HRD and PARPi/platinum
• MMRd and PD-1/PD-L1
• CDK12 mutations and PD-1/PD-L1
• PTEN loss and AKTi
• SPOP: Do very well on abiraterone
• WNT and poor ARSI response
• RB1/TP53: Poor outcome (low PSMA)
• Luminal to basal switch
Robinson et al, Cell 2015; Kumar et al, Nature Medicine 2016; Gundem et al, Nature 2015; Nava Rodrigues et al, JCI 2018